-
公开(公告)号：EP1685121B1
公开(公告)日：2008-06-11
申请号：EP04790858.7
申请日：2004-10-26
申请人： Merck Patent GmbH
IPC分类号： C07D333/64 , C07D307/83 , A61K31/381 , A61K31/343
CPC分类号： A61K31/381 , A61K31/343 , C07D333/68 , C07D333/70
摘要： The invention relates to compounds of the general formula (I) in which R1, R2, R3, R4, R5, R6 and X are as defined in Claim 1. These compounds can be used in the treatment of pathologies associated with insulin resistance syndrome.
-
22.发明公开
公开(公告)号：EP1761486A1
公开(公告)日：2007-03-14
申请号：EP05749839.6
申请日：2005-06-01
申请人： Merck Patent GmbH
IPC分类号： C07C311/21 , C07C311/46 , C07C311/08 , C07C311/29 , C07C311/13 , C07C311/44 , C07C311/10 , C07D277/46 , C07D333/34 , C07D333/62 , C07D215/36 , C07C233/81 , C07C233/54 , C07C233/55 , C07C235/24
CPC分类号： C07C311/21 , C07C233/25 , C07C233/26 , C07C233/27 , C07C233/29 , C07C233/48 , C07C233/54 , C07C233/55 , C07C233/63 , C07C233/75 , C07C233/81 , C07C235/16 , C07C235/24 , C07C235/38 , C07C235/48 , C07C235/56 , C07C237/42 , C07C311/08 , C07C311/10 , C07C311/13 , C07C311/29 , C07C311/44 , C07C311/46 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/42 , C07D215/36 , C07D277/46 , C07D307/68 , C07D333/34 , C07D333/38 , C07D333/62
摘要： The invention relates to compounds of general formula (1): in which R1, R2, R3, R4, R5, A, B, D and E are as defined in Claim 1, and also to the preparation process therefor and the therapeutic use thereof. These compounds can be used in the treatment of pathologies associated with hyperglycaemia.
摘要翻译： 本发明涉及通式（1）的化合物：其中R1，R2，R3，R4，R5，A，B，D和E如权利要求1所定义，以及其制备方法及其治疗用途 。 这些化合物可用于治疗与高血糖相关的病理。
-
公开(公告)号：EP0925273B1
公开(公告)日：2001-11-07
申请号：EP97936682.0
申请日：1997-08-05
申请人： MERCK PATENT GmbH
IPC分类号： C07C59/84 , A61K31/19 , C07D307/77 , C07D317/60 , C07C59/86 , C07C59/88 , C07C59/90
CPC分类号： C07D317/60 , C07C59/84 , C07C69/738 , C07D307/16
摘要： The invention concerns a pharmaceutical composition containing, as active principle, a compound of formula (a) in which groups A and B are selected independently of each other among: a mono-cyclic, bi-cyclic or tri-cyclic aryl group having 6 to 14 carbon atoms; a heteroaraomatic group selected among the pyridyl, pyrimidyl, pyrrolyl, furyl and thienyl groups; an alkyl group having 1 to 14 carbon atoms; a cycloalkyl group having 5 to 8 carbon atoms; a saturated heterocyclic group selected among the tetrahydrofuryl, tetrahydropyrranyl, piperidinyl and pyrrolidinyl groups; its solvate or a salt of this acid with a pharmaceutically acceptable base.
-
24.发明公开((AMINOIMINOMETHYL) AMINO) ALKANECARBOXAMIDES AND THEIR APPLICATIONS IN THERAPY 有权（（氨基二甲氨基）氨基）阿尔卡菌素在治疗方案中维生素B
公开(公告)号：EP1140803A1
公开(公告)日：2001-10-10
申请号：EP99964687.0
申请日：1999-12-30
申请人： MERCK PATENT GmbH
IPC分类号： C07C279/14 , C07D295/18 , C07D213/75 , A61K31/16 , A61K31/435 , A61P3/00
CPC分类号： C07D213/75 , C07C279/14 , C07C2601/16 , C07D295/185
摘要： The invention relates to a pharmaceutical composition comprising as active principle a compound of general formula (I), in which R1, R2, R3 and A are as defined in Claim 1. These compositions can be used in the treatment of pathologies associated with insulin resistance syndrome.
摘要翻译： 本发明涉及包含作为活性成分的通式（I）化合物的药物组合物，其中R 1，R 2，R 3和A如权利要求1中所定义。这些组合物可用于治疗与胰岛素抵抗相关的病症 综合征。
-
25.发明公开ANTIDIABETIC PIPERAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM 审中-公开抗糖尿病哌嗪衍生物，用于生产和含有组合物
公开(公告)号：EP1100790A1
公开(公告)日：2001-05-23
申请号：EP99936561.2
申请日：1999-07-17
申请人： MERCK PATENT GmbH
IPC分类号： C07D295/08 , A61K31/495 , C07D213/72 , C07D239/42 , C07D277/82
CPC分类号： C07D239/42 , C07D213/74 , C07D277/82 , C07D295/088
摘要： The invention relates to novel piperazine derivatives of formula (I) wherein (Z)i, X, N and Ar have the meanings as given in claim 1, and which are of use in the treatment of pathologies associated with insulin-resistance syndrome.
-
公开(公告)号：EP0925273A1
公开(公告)日：1999-06-30
申请号：EP97936682.0
申请日：1997-08-05
申请人： MERCK PATENT GmbH
CPC分类号： C07D317/60 , C07C59/84 , C07C69/738 , C07D307/16
摘要： The invention concerns a pharmaceutical composition containing, as active principle, a compound of formula (a) in which groups A and B are selected independently of each other among: a mono-cyclic, bi-cyclic or tri-cyclic aryl group having 6 to 14 carbon atoms; a heteroaraomatic group selected among the pyridyl, pyrimidyl, pyrrolyl, furyl and thienyl groups; an alkyl group having 1 to 14 carbon atoms; a cycloalkyl group having 5 to 8 carbon atoms; a saturated heterocyclic group selected among the tetrahydrofuryl, tetrahydropyrranyl, piperidinyl and pyrrolidinyl groups; its solvate or a salt of this acid with a pharmaceutically acceptable base.
-
27.发明公开
公开(公告)号：EP0918759A1
公开(公告)日：1999-06-02
申请号：EP97925034.0
申请日：1997-06-02
申请人： MERCK PATENT GmbH
发明人： MOINET, Gérard , BOTTON, Gérard , PRUGNARD, Etienne , DOARE, Liliane , KERGOAT, Micheline , MESANGEAU, Didier
CPC分类号： C07D277/34
摘要： The invention relates to the field of chemistry and more particularly to that of therapeutic chemistry. The invention more precisely features novel 5-phenoxyalkyl 2,4-thiazolidinediketones of general formula (I): in which A represents one linear or branched alkylene group comprising 2 to 16 carbon atoms D represents one monocyclic, bycyclic or tricyclic, homocarbonaceous or heterocarbonaceous aromatic structure capable of enclosing one or several heteroatoms X represents the aromatic structure substituent and is as defined in claim 1 n is one integer ranging from 1 to 3 with the restriction that if A represents one butyl radical, (a) does not represent the 4-chlorophenyl group. The invention also disclosed tautomer, enantiomer, diastereoisomer and epimer forms of general formula (I) compounds, in free or salified form. The invention also discloses methods for obtaining general formula (I) compounds, their use as antidiabetic agents, and in the insulin resistance metabolic syndrome, as well as in the pharmaceutical compositions that contain general formula (I) compounds.
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.015 秒)
